221 related articles for article (PubMed ID: 11703844)
1. Monitoring drug resistance in leishmaniasis.
Croft SL
Trop Med Int Health; 2001 Nov; 6(11):899-905. PubMed ID: 11703844
[TBL] [Abstract][Full Text] [Related]
2. Drug resistance in leishmaniasis.
Croft SL; Sundar S; Fairlamb AH
Clin Microbiol Rev; 2006 Jan; 19(1):111-26. PubMed ID: 16418526
[TBL] [Abstract][Full Text] [Related]
3. Paromomycin in the treatment of leishmaniasis.
Sundar S; Chakravarty J
Expert Opin Investig Drugs; 2008 May; 17(5):787-94. PubMed ID: 18447603
[TBL] [Abstract][Full Text] [Related]
4. In Vitro Growth Inhibition Assays of Leishmania spp.
Hendrickx S; Caljon G; Maes L
Methods Mol Biol; 2020; 2116():791-800. PubMed ID: 32221956
[TBL] [Abstract][Full Text] [Related]
5. Drug resistance and treatment failure in leishmaniasis: A 21st century challenge.
Ponte-Sucre A; Gamarro F; Dujardin JC; Barrett MP; López-Vélez R; García-Hernández R; Pountain AW; Mwenechanya R; Papadopoulou B
PLoS Negl Trop Dis; 2017 Dec; 11(12):e0006052. PubMed ID: 29240765
[TBL] [Abstract][Full Text] [Related]
6. Impact of primary mouse macrophage cell types on Leishmania infection and in vitro drug susceptibility.
Van den Kerkhof M; Van Bockstal L; Gielis JF; Delputte P; Cos P; Maes L; Caljon G; Hendrickx S
Parasitol Res; 2018 Nov; 117(11):3601-3612. PubMed ID: 30141075
[TBL] [Abstract][Full Text] [Related]
7. Mechanisms of drug action and drug resistance in Leishmania as basis for therapeutic target identification and design of antileishmanial modulators.
Loiseau PM; Bories C
Curr Top Med Chem; 2006; 6(5):539-50. PubMed ID: 16719806
[TBL] [Abstract][Full Text] [Related]
8. Treatment failure in leishmaniasis: drug-resistance or another (epi-) phenotype?
Vanaerschot M; Dumetz F; Roy S; Ponte-Sucre A; Arevalo J; Dujardin JC
Expert Rev Anti Infect Ther; 2014 Aug; 12(8):937-46. PubMed ID: 24802998
[TBL] [Abstract][Full Text] [Related]
9. Evaluating drug resistance in visceral leishmaniasis: the challenges.
Hendrickx S; Guerin PJ; Caljon G; Croft SL; Maes L
Parasitology; 2018 Apr; 145(4):453-463. PubMed ID: 27866478
[TBL] [Abstract][Full Text] [Related]
10. Leishmaniasis: efflux pumps and chemoresistance.
Leandro C; Campino L
Int J Antimicrob Agents; 2003 Sep; 22(3):352-7. PubMed ID: 13678842
[TBL] [Abstract][Full Text] [Related]
11. Leishmaniasis--current chemotherapy and recent advances in the search for novel drugs.
Croft SL; Coombs GH
Trends Parasitol; 2003 Nov; 19(11):502-8. PubMed ID: 14580961
[No Abstract] [Full Text] [Related]
12. Leishmania spp.: proficiency of drug-resistant parasites.
Natera S; Machuca C; Padrón-Nieves M; Romero A; Díaz E; Ponte-Sucre A
Int J Antimicrob Agents; 2007 Jun; 29(6):637-42. PubMed ID: 17353113
[TBL] [Abstract][Full Text] [Related]
13. American tegumentary leishmaniasis: Is antimonial treatment outcome related to parasite drug susceptibility?
Yardley V; Ortuno N; Llanos-Cuentas A; Chappuis F; Doncker SD; Ramirez L; Croft S; Arevalo J; Adaui V; Bermudez H; Decuypere S; Dujardin JC
J Infect Dis; 2006 Oct; 194(8):1168-75. PubMed ID: 16991093
[TBL] [Abstract][Full Text] [Related]
14. The fitness of antimony-resistant Leishmania parasites: lessons from the field.
Ait-Oudhia K; Gazanion E; Oury B; Vergnes B; Sereno D
Trends Parasitol; 2011 Apr; 27(4):141-2. PubMed ID: 21216196
[No Abstract] [Full Text] [Related]
15. Development and evaluation of a cedrol-loaded nanostructured lipid carrier system for in vitro and in vivo susceptibilities of wild and drug resistant Leishmania donovani amastigotes.
Kar N; Chakraborty S; De AK; Ghosh S; Bera T
Eur J Pharm Sci; 2017 Jun; 104():196-211. PubMed ID: 28400285
[TBL] [Abstract][Full Text] [Related]
16. Exploiting Knowledge on Leishmania Drug Resistance to Support the Quest for New Drugs.
Hefnawy A; Berg M; Dujardin JC; De Muylder G
Trends Parasitol; 2017 Mar; 33(3):162-174. PubMed ID: 27993477
[TBL] [Abstract][Full Text] [Related]
17. Treatment of leishmaniasis: a review and assessment of recent research.
Elmahallawy EK; Agil A
Curr Pharm Des; 2015; 21(17):2259-75. PubMed ID: 25543123
[TBL] [Abstract][Full Text] [Related]
18. Emerging role of amiodarone and dronedarone, as antiarrhythmic drugs, in treatment of leishmaniasis.
Oryan A; Bemani E; Bahrami S
Acta Trop; 2018 Sep; 185():34-41. PubMed ID: 29689189
[TBL] [Abstract][Full Text] [Related]
19. Meglumine antımoniate-TiO2@Ag nanoparticle combinations reduce toxicity of the drug while enhancing its antileishmanial effect.
Abamor ES; Allahverdiyev AM; Bagirova M; Rafailovich M
Acta Trop; 2017 May; 169():30-42. PubMed ID: 28111133
[TBL] [Abstract][Full Text] [Related]
20. Cellular Markers for the Identification of Chemoresistant Isolates in Leishmania.
Padrón-Nieves M; Ponte-Sucre A
Methods Mol Biol; 2020; 2116():755-769. PubMed ID: 32221953
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
